GLUE Stock Catalyst: Monte Rosa Therapeutics Announces Collaboration with Novartis for Immune-Mediated Disease Degraders

Sep 15, 2025 · 7:00am ET

Deal includes $120 million upfront and up to $5.7 billion in total value.

Max move

+79.8%

High of day $9.17

Sparker timei

7:00am ET

GLUE · Sep 15, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Monte Rosa Therapeutics, Inc. and Novartis announced on September 15, 2025 Monte Rosa Therapeutics announced a collaboration with Novartis to develop novel degraders for immune-mediated diseases.

Up to $5.7 billion in total deal value. Tiered royalties on global net sales in the high single to low double-digit range. The announcement cited $120 million upfront payment.

Monte Rosa Therapeutics, Inc. has a free float of 28,946,100 shares and 65,118,000 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time GLUE sparks.

Download Sniper App →

Catch the next GLUE-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →